BACKGROUND: Cancer immunotherapy is associated with several immune-related adverse events, but the relationship between immunotherapy and venous thromboembolism has not been thoroughly studied. METHODS: We conducted a retrospective cohort study of 1,686 patients who received immunotherapy for a variety of malignancies to determine the incidence of venous thromboembolism and the impact of venous thromboembolism on survival. To examine the potential role of inflammation in venous thromboembolism, we also profiled immune cells and plasma cytokines in blood samples obtained prior to initiation of immunotherapy in a sub-cohort of patients treated on clinical trials who subsequently did (N = 15), or did not (N = 10) develop venous thromboembolism. FINDINGS: Venous thromboembolism occurred while on immunotherapy in 404/1686 patients (24%) and was associated with decreased overall survival [HR=1.22 (95% CI 1.06-1.41), p<0.008]. Patients that developed venous thromboembolism had significantly higher pretreatment levels of myeloid-derived suppressor cells (5.382 ± 0.873 vs. 3.341 ± 0.3402, mean ± SEM; p=0.0045), interleukin 8 (221.2 ± 37.53 vs. 111.6 ± 25.36, mean ± SEM; p=0.016), and soluble vascular cell adhesion protein 1 (1210 ± 120.6 vs. 895.5 ± 53.34, mean ± SEM; p=0.0385). CONCLUSIONS: These findings demonstrate that venous thromboembolism is an underappreciated and important immune-related adverse event associated with cancer immunotherapy, and may implicate an interleukin 8 and myeloid-derived suppressor cell-driven pathway in pathogenesis.
BACKGROUND: Cancer immunotherapy is associated with several immune-related adverse events, but the relationship between immunotherapy and venous thromboembolism has not been thoroughly studied. METHODS: We conducted a retrospective cohort study of 1,686 patients who received immunotherapy for a variety of malignancies to determine the incidence of venous thromboembolism and the impact of venous thromboembolism on survival. To examine the potential role of inflammation in venous thromboembolism, we also profiled immune cells and plasma cytokines in blood samples obtained prior to initiation of immunotherapy in a sub-cohort of patients treated on clinical trials who subsequently did (N = 15), or did not (N = 10) develop venous thromboembolism. FINDINGS: Venous thromboembolism occurred while on immunotherapy in 404/1686 patients (24%) and was associated with decreased overall survival [HR=1.22 (95% CI 1.06-1.41), p<0.008]. Patients that developed venous thromboembolism had significantly higher pretreatment levels of myeloid-derived suppressor cells (5.382 ± 0.873 vs. 3.341 ± 0.3402, mean ± SEM; p=0.0045), interleukin 8 (221.2 ± 37.53 vs. 111.6 ± 25.36, mean ± SEM; p=0.016), and soluble vascular cell adhesion protein 1 (1210 ± 120.6 vs. 895.5 ± 53.34, mean ± SEM; p=0.0385). CONCLUSIONS: These findings demonstrate that venous thromboembolism is an underappreciated and important immune-related adverse event associated with cancer immunotherapy, and may implicate an interleukin 8 and myeloid-derived suppressor cell-driven pathway in pathogenesis.
Authors: Nick van Es; Yohei Hisada; Marcello Di Nisio; Gabriela Cesarman; Ankie Kleinjan; Isabelle Mahé; Hans-Martin Otten; Pieter W Kamphuisen; René J Berckmans; Harry R Büller; Nigel Mackman; Rienk Nieuwland Journal: Thromb Res Date: 2018-04-10 Impact factor: 3.944
Authors: Kristina N Ekdahl; Yuji Teramura; Osama A Hamad; Sana Asif; Claudia Duehrkop; Karin Fromell; Elisabet Gustafson; Jaan Hong; Huda Kozarcanin; Peetra U Magnusson; Markus Huber-Lang; Peter Garred; Bo Nilsson Journal: Immunol Rev Date: 2016-11 Impact factor: 12.988
Authors: Alice Tzeng; C Marcela Diaz-Montero; Patricia A Rayman; Jin S Kim; Paul G Pavicic; James H Finke; Pedro C Barata; Marcelo Lamenza; Sarah Devonshire; Kim Schach; Hamid Emamekhoo; Marc S Ernstoff; Christopher J Hoimes; Brian I Rini; Jorge A Garcia; Timothy D Gilligan; Moshe C Ornstein; Petros Grivas Journal: Target Oncol Date: 2018-10 Impact factor: 4.493
Authors: Ella Grilz; Christine Marosi; Oliver Königsbrügge; Julia Riedl; Florian Posch; Wolfgang Lamm; Irene M Lang; Ingrid Pabinger; Cihan Ay Journal: J Thromb Haemost Date: 2019-06-17 Impact factor: 5.824
Authors: Alok A Khorana; Nigel Mackman; Anna Falanga; Ingrid Pabinger; Simon Noble; Walter Ageno; Florian Moik; Agnes Y Y Lee Journal: Nat Rev Dis Primers Date: 2022-02-17 Impact factor: 65.038